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SNX10 gene mutation leading to 
osteopetrosis with dysfunctional 
osteoclasts
Eva-Lena Stattin1,2, Petra Henning3, Joakim Klar  2, Emma McDermott4, Christina Stecksen-
Blicks5, Per-Erik Sandström6, Therese G. Kellgren7, Patrik Rydén7, Göran Hallmans8, Torsten 
Lönnerholm9, Adam Ameur2, Miep H. Helfrich4, Fraser P. Coxon4, Niklas Dahl2, Johan 
Wikström9 & Ulf H. Lerner3,10
Autosomal recessive osteopetrosis (ARO) is a heterogeneous disorder, characterized by defective 
osteoclastic resorption of bone that results in increased bone density. We have studied nine individuals 
with an intermediate form of ARO, from the county of Västerbotten in Northern Sweden. All afflicted 
individuals had an onset in early infancy with optic atrophy, and in four patients anemia was present 
at diagnosis. Tonsillar herniation, foramen magnum stenosis, and severe osteomyelitis of the jaw 
were common clinical features. Whole exome sequencing, verified by Sanger sequencing, identified a 
splice site mutation c.212 + 1 G > T in the SNX10 gene encoding sorting nexin 10. Sequence analysis 
of the SNX10 transcript in patients revealed activation of a cryptic splice site in intron 4 resulting in a 
frame shift and a premature stop (p.S66Nfs * 15). Haplotype analysis showed that all cases originated 
from a single mutational event, and the age of the mutation was estimated to be approximately 
950 years. Functional analysis of osteoclast progenitors isolated from peripheral blood of patients 
revealed that stimulation with receptor activator of nuclear factor kappa-B ligand (RANKL) resulted in 
a robust formation of large, multinucleated osteoclasts which generated sealing zones; however these 
osteoclasts exhibited defective ruffled borders and were unable to resorb bone in vitro.
In healthy individuals, normal bone homeostasis is maintained by balancing bone resorption by osteoclasts 
with new bone formation by osteoblasts. Osteopetrosis constitutes a heterogeneous group of rare disorders 
characterized by increased bone mass caused either by an inability to form osteoclasts or by loss of osteoclast 
function1–4. Bone resorbing multinucleated osteoclasts are formed by the differentiation and fusion of mono-
nuclear hematopoietic precursor cells in the monocyte lineage. Their differentiation is mediated by macrophage 
colony-stimulating factor (M-CSF), which is required for proliferation and survival of the mononucleated cells, 
and receptor activator of nuclear factor kB ligand (RANKL), which triggers differentiation along the osteoclastic 
lineage. The main clinical features of osteopetrosis are an increased bone density with brittle bones and multiple 
fractures, narrowing of foramina in the skull with neurological symptoms, and reduced bone marrow cavities 
leading to impaired hematopoiesis, anemia and recurrent infections4, 5.
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Autosomal recessive osteopetrosis (ARO) comprises the infantile, or “malignant” form, and a less severe inter-
mediate form (IARO). In malignant ARO, the skeletal defects have an onset before birth and the resulting nerve 
damage due to entrapment is irreversible. Treatment with hematopoietic stem cell transplantation (HSCT) is 
critical in order to prevent disease progression and early death4, 6. To date, at least 10 genes coding for osteo-
clast function or osteoclast differentiation have been demonstrated to be causally involved in the pathogenesis of 
osteopetrosis1–4. The incidence of ARO is estimated to be 1 in 250,000 births, but can be much higher in isolated 
consanguineous populations7–9.
Recently, a missense mutation in the gene encoding sorting nexin 10 (SNX10 [MIM614780]) was shown to 
be the cause of ARO (OPTB8 [MIM615085]) in consanguineous families of Palestinian origin10. Since then, dif-
ferent mutations in the SNX10 gene have been reported in osteopetrosis patients of diverse ethnicities11, 12. At the 
initiation of the present study, we were aware of several cases with osteopetrosis of unknown origin in the county 
of Västerbotten, Sweden. A genealogy study revealed that the patients belonged to the same family. We therefore 
performed exome sequencing with the aim to find the pathogenic sequence variant causing the disease and, in 
addition, performed cellular and functional studies to assess the role of the mutation in bone remodeling. During 
the course of our studies, three patients with osteopetrosis from the Västerbotten County were reported to have 
a mutation in the SNX10 gene12. We confirmed that all osteopetrosis patients in the Västerbotten County carry 
the same SNX10 mutation. Here, we describe the clinical features and natural course of the disease in the largest 
cohort of patients with IARO reported thus far. We identified the disease-causing mutation in SNX10, as well as its 
origin and age and report detailed functional analyses on osteoclasts carrying this pathogenic sequence variant.
Results
Subjects. We studied nine patients, five males and four females, with IARO from the county of Västerbotten 
in Northern Sweden. The clinical data are summarized in Table 1.
Manifestation of the disease was seen in early infancy in all patients, but the age at correct diagnosis varied 
from 7 weeks (Pt1) to 3 years (Pt9). The patient (Pt9) diagnosed at the age of 3 years was first thought to have a 
hereditary optic atrophy. Delayed tooth eruption prompted radiology and the diagnosis of osteopetrosis became 
apparent (Fig. 1A–D).
Skeletal features, radiographs and fractures. Birth length was within ±2 SD (range 48–52 cm), and 
head circumference ±1 SD (range 34–35 cm). All patients had short final height (males: 132 cm, (−6.7 SD), 
160 cm, (−2.5 SD), females: 149 cm, (−2.5 SD), 159 cm, (−1.1 SD) (Table 1)). In all patients, skeletal radiographs 
show a generalized increase in bone density with metaphyseal modelling defects, transverse bands of greater 
and lesser density in tubular bones, short wide femoral neck, and”bone-within-bone” pattern of the phalanges 
(Fig. 1A–D). There were no radiological signs of rickets in five evaluated patients (Pt1, Pt5, and Pt7–9). Seven of 
nine patients suffered from recurrent fractures up to about 30 times (Pt1), even after minor trauma. During child-
hood, almost all fractures were transverse diaphyseal fractures in the extremities without pronounced dislocation 
and they healed normally with periosteal callus. The adult patients (Pt1–5) also had femoral shaft fractures with 
prolonged healing or pseudoarthrosis despite external or internal fixation. One boy (Pt7), who received hemato-
poietic stem cell transplantation (HSCT), did not fracture and his growth normalized (Table 1).
Neurological symptoms. All patients developed visual impairment before the age of one year, and five 
patients became blind (Pt1, Pt4, Pt6, Pt8, and Pt9). Decompression of the optic nerve was not performed in any of 
the patients. Retinal atrophy was not observed. All but one patient suffers or suffered from hearing impairment, 
and one patient (Pt6) developed a profound deafness (Table 1).
After birth, the head circumference increased rapidly in six patients. One girl (Pt9) was found to have hydro-
cephalus and cerebellar tonsillar herniation, requiring a ventriculo-peritoneal shunt. She was operated at the age 
of eight years with decompression of the brainstem, and she died unexpectedly, two years later, possibly due to 
compression of a postsurgical cephalocele. At that time, she was hospitalized for evaluation of severe back pain, 
and headache episodes. Two patients (Pt8, and Pt5) developed stenosis of the foramen magnum; one (Pt8) died 
at the age of 12 years due to spinal cord compression while the other (Pt5) is still alive at the age of 24 years. One 
boy (Pt6) showed intellectual disability in addition to early blindness and profound deafness. Facial paralysis was 
present in four patients (Pt1–4).
Evaluation of six magnetic resonance imaging (MRI), and three computed tomography (CT) scans showed 
a thickened and sclerotic bone of the skull in all but one patient (Table 2). Scans did not show brain malforma-
tions (Fig. 1E,F).
Hematological symptoms. Anemia was present early in life in four patients (Pt1, Pt2, Pt7, and Pt9) due to bone 
marrow encroachment. Consumption and hemolysis of erythrocytes, followed by a low leucocyte count and throm-
bocytopenia, was seen in two patients (Pt8, and Pt9); haptoglobin and carboxyhemoglobin (CoHb) were below the 
detection limit. Splenectomies were performed on these patients and the hematopoiesis almost normalized afterwards. 
Six of nine patients require or required repeated blood transfusions due to normocytic anemia (Table 1).
All patients were offered stem cell transplantation, most of them during adolescence, but HSCT was accepted 
only by the parents of the youngest one (Pt7). He received HSCT at the age of 33 months from an HLA-matched 
unrelated donor; he is still alive and healthy at the age of 15 years. However, he suffers from irreversible tissue 
damage that occurred prior to transplantation: he has visual deterioration as well as missing and malformed teeth.
Two patients (Pt4, and Pt6) died due to a combination of pancytopenia and septicemia; one (Pt6) died at the age of 
19, due to septicemia originating from osteomyelitis of the jaw, and the other (Pt4) died at the age of 35, due to chronic 
osteomyelitis of one femur after an unhealed fracture. Autopsy was not performed in any of the patients (Table 1).
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Patient number 1 2 3 4 5 6 7 8 9
Gender Male Female Male Female Female Male Male Male Female
age (year) 47 43 46 35 24 19 15 12 10
Birth length, 
weight, AOFC
51 cm 50 cm 52 cm BNA 48 cm 52 cm NA (±0SD) NA 48 cm
4000 g 3620 g 3910 g 3110 g 2930 g 3500 g 3094 g NA 3305 g
34 cm NA NA NA NA 34.5 cm NA NA 35 cm
Final height 
(age year) C(SD)
132 cm 149 cm 160 cm 159 cm NA NA Normal growth, after DHSCT — —
(17)(−6.7) (20)(−2.5) (20)(−2.9) (19)(−1.1)
Age at onset Early infancy Early infancy Early infancy Early infancy Early infancy Early infancy Early infancy Early infancy Early infancy
Age at 
diagnosis, 
Esymptoms
7 weeks. Optic atrophy. 
Macrocephaly. 
Anaemia (FHb 
6.64 mmol/l)
5 months. 
Optic atrophy. 
Macrocephaly 
46 cm. 
Anaemia (Hb 
6.09 mmol/l)
2 years. Optic 
atrophy. 
Macrocephaly
6 months. 
Optic atrophy. 
Macrocephaly 
44.5 cm
19 months. 
Optic atrophy. 
Macrocephaly 
50 cm
12 months. 
Optic atrophy, 
blindness
28 months. 
Optic atrophy. 
Macrocephaly 
55.5 cm. 
Anaemia (Hb 
6.33 mmol/l)
Days, disease 
known in the 
family
36 months. 
Retained 
teeth. Nasal 
congestion. 
Optic atrophy. 
Macrocephaly. 
Anaemia (Hb 
6.6 mmol/l)
Stem cell 
transplantation — — — — — —
HSCT at the age 
of 33 month — —
Deceased (age) — — — 35 years — 19 years — 12 years 10 years
Neurological 
symptoms
Blindness. Impaired 
hearing, unilateral 
profound deafness. 
Facial paralysis
Impaired vision, 
(blind on one 
eye). Impaired 
hearing. Facial 
paralysis
Impaired vision, 
(blind on one 
eye). Impaired 
hearing, tuba 
aperta. Facial 
paralysis
Blindness. 
Impaired 
hearing. Facial 
paralysis
Impaired vision 
and hearing. 
Foramen 
magnum 
stenosis, op 
decompression 
at the age of 14
Blindness. 
Profound 
deafness. 
Intellectual 
disability
Impaired vision
Blindness. 
Impaired 
hearing. 
Died due 
to foramen 
magnum 
stenosis at the 
age of 12
Blindness. 
Hydrocephalus, 
GVP-shunt. 
Decompression 
op of the 
brainstem at 
the age of 8, 
died due to 
compression of 
a postsurgical 
cephalocele
Haematological 
symptoms
Anaemia, hepato-
splenomegaly, 
splenectomy at 
the age of 5. Blood 
transfusions.
Anaemia, 
hepato-
splenomegaly. 
Blood 
transfusions.
Anaemia, 
hepato-
splenomegaly. 
Blood 
transfusions.
Anaemia, 
hepato-
splenomegaly. 
Blood 
transfusions 
Died due to 
septicaemia 
originating 
from 
osteomyelitis.
Almost normal 
haematopoiesis.
Anaemia, 
hepato-
splenomegaly.
Normal 
haematopoiesis.
Anaemia, 
hepato-
splenomegaly, 
splenectomy 
at the age 
of 9. Blood 
transfusions.
Anaemia, 
hepato-
splenomegaly, 
splenectomy 
at the age 
of 5. Blood 
transfusions.
Eruption of 
primary teeth 
(month), 
and teeth 
development
NA   
Malformed and 
retained
At the age of 
4-6 months, ten 
primary teeth 
Malformed and 
retained
At the age of 
6 months, five 
primary teeth 
Malformed and 
retained
NA   
Malformed and 
retained
At the age of 
6 months, 12 
primary teeth 
Malformed and 
retained
NA 
Malformed 
and retained
At the age of  
28 months, two 
primary teeth 
Malformed and 
retained but a 
lot better than 
patients not 
transplanted
At the age of 
13 months, six 
primary teeth 
Malformed 
and retained
At the age of  
31 months, 
eight primary 
teeth 
Malformed and 
retained
HONJ (year)
At the age of 6. 
Osteonecrosis of the 
ear canal, and the 
skull with associated 
epidural abscess
At the age of 13. 
Osteonecrosis 
of the ear canal
At the age of 30. 
Osteonecrosis 
of the ear canal
ONJ (age NA) At the age of 18.
At the age of 
12. Died due 
to septicaemia 
originating 
from ONJ
None None None
Airway 
symptoms
Narrow nasal, and 
pharynx cavities 
Tracheostomy at the 
age of 22. ICPAP during 
night
Early nasal 
obstruction, 
before the age 
of 5 months. 
CPAP during 
night
Narrow nasal, 
and pharynx 
cavities CPAP 
during night 
since the age 
of 35.
Narrow nasal, 
and pharynx 
cavities
Narrow nasal, 
and pharynx 
cavities
Narrow nasal, 
and pharynx 
cavities
None
Narrow nasal, 
and pharynx 
cavities 
Apnoea during 
the night 
Tracheostomy 
at the age of 9.
Nasal 
obstruction, 
before the age 
of 12 month, 
adenoidectomy 
Tracheostomy 
at the age of 8.
Bone fractures Multiple fractures, pseudoarthrosis
Multiple 
fractures, 
pseudoarthrosis
Multiple 
fractures, 
pseudoarthrosis
Multiple 
fractures, 
pseudoarthrosis
Multiple 
fractures
Multiple 
fractures None
Multiple 
fractures Few fractures
Other features
Exophthalmos keratitis, 
endophthalmitis, 
enucleation of one 
eye. Ear canal stenosis, 
Kidney tumour, 
Urinary stones, Weight 
loss, Wheelchair bound
Exophthalmos 
Drooling, 
treated 
with Botox, 
Wheelchair 
bound
Exophthalmos, 
Bilat pes 
calcaneovalgus, 
Hypertension, 
Walking frame
Exophthalmos 
Media otitis, 
Wheelchair 
bound
Exophthalmos, 
Mitral valve 
insufficiency, 
Wheelchair 
bound
Exophthalmos 
Inguinal 
hernia, 
Wheelchair 
bound
Exophthalmos
Exophthalmos, 
Drooling, 
Anosmia
Exophthalmos, 
Severe back 
pain
Table 1. Clinical features of nine individuals with a splice site mutation in the SNX10 gene, and intermediate 
autosomal recessive osteopetrosis (IARO). AOFC = occipital-frontal circumference. BNA = Not available. 
CSD = Standard deviations. DHSCT = hematopoietic stem cell transplantation. ESymptoms that lead to 
the diagnosis. FHb = hemoglobin. GVP = ventriculo-peritoneal shunt. HONJ = osteonecrosis of the jaw. 
ICPAP = continuous positive airway pressure.
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Symptoms of the airways, jaw and teeth. All patients had narrow nasal, and pharyngeal cavities, and 
two patients (Pt2, and Pt9) had documented nasal congestion before the age of one year. Three patients (Pt1, 
Pt8, and Pt9) needed a tracheostomy at the age of 8, 9 and 22 years, respectively. Three adult patients (Pt1–3) are 
treated with continuous positive airway pressure (CPAP) during nighttime, due to sleep apnea syndrome. Tooth 
Figure 1. A Radiographs of subjects with the Västerbotten form of intermediate osteopetrosis, and sequencing 
of the SNX10 gene. (A–D) Skeletal radiographs of a girl at the age of three years (Pt9), showing characteristic 
features of intermediate osteopetrosis. (A) Skull: Increased bone density of the skull base, frontal bossing 
and VP-shunt (B) AP view of the legs: “Erlenmeyer flask” shape of the femoral diaphysis. Longitudinal and 
transverse bands of lesser density in the metaphyses. Bone-within-bone pattern in the epiphyses in the knee. 
(C) Lateral view of the spine: Very dens endplates of the vertebral bodies, so called “sandwich vertebrae”. The 
ribs (seen in part) are broad and dens. (D) AP view of the left arm: No fractures or sign of rickets, “bone-
within-bone” pattern of the phalanges. (E,F) Magnetic resonance imaging of the brain, and spine in an 
11-year-old boy. MRI shows cerebellar tonsillar descent through the foramen magnum, a foramen magnum 
narrowing, and signs of brain stem compression with resulting syringo-hydromyelia. (G,H) Consequence of the 
c.212 + 1 G > T variant on (G) genomic level and (H) transcript level. (G) Sequencing of DNA from a control 
(top), a heterozygous carrier (middle) and a homozygous patient (bottom) for the c.212 + 1 G > T variant. The 
variant changes the donor splice site at the 5′ end of intron 4 from GT to TT. This leads to a predicted use of an 
alternative donor splice site 16 nucleotides upstream of intron 4. (H) Sequencing of cDNA from a control (top) 
and a patient (bottom) confirms the use of an alternative splice site and the skipping of 16 bp leading to a frame 
shift and a premature stop codon (p.S66Nfs * 15) at the protein level.
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eruption was delayed in three patients (Pt7–9), and teeth are congenitally missing, malformed or retained in all 
patients. Severe osteomyelitis and osteonecrosis of the jaw is seen in all adult patients (Pt1–6), with abscess for-
mations and fistulas to the orbits and skin. One patient (Pt1) presented with osteonecrosis of the jaw at the age of 
six years, other patients (Pt2, Pt3, Pt5, and Pt6) at the age of 12, 13, 18 and 30 years, respectively. Osteonecrosis of 
the ear canal is seen in three of the eldest patients (Pt1–3) (Table 1).
Exome sequencing, data filtering, DNA and cDNA sequencing, carrier frequency. Exome 
sequencing of three patients (Pt1, Pt2, and Pt5) revealed 115,283 unique SNPs. Among those, 25,301 were com-
mon, 24,867 remained after excluding SNPs on chromosomes X and Y, and 9,401 were homozygous. Nineteen of 
those were not present in the control population and three were non-synonymous, and located in three different 
genes. One of the three genes was the SNX10 gene. Homozygous sequence variants at the donor splice site of exon 
4 (c.212 + 1 G > T) were confirmed in all affected patients using Sanger sequencing, and the parents were found 
to be heterozygous for the splice site mutation (Fig. 1G–H). The splice site variant is not present in any of >1000 
exomes present in our local Canvas DB, or in controls in Exome Seq. project or 1000 Genomes13, 14. Sequence 
analysis of cDNA from cultured patient peripheral blood cells revealed that an alternative splice site, located 16 
bases upstream from intron 4, was used, resulting in a frame shift and a stop codon (p.S66Nfs * 15). The carrier 
frequency of the sequence variant in the county of Västerbotten is 1:93 or 1.1% of the population.
Genealogy and haplotype analysis. Genealogic data revealed a common ancestor 8–12 generations 
back, in the early 19th century. He was born 1820 in Bureå, Skellefteå, County of Västerbotten, northern Sweden. 
Haplotype analysis was performed to evaluate the age of the sequence variant. The size of the homozygous 
regions in Pts1–5 is 4044451 bp, 3494094 bp, 3515023 bp, 5632740 bp, 4628862 bp, and 4628862 bp, respectively. 
Pt9 showed homozygosity between marker rs477644 and rs6462058, corresponding to 11307603 bp, which was 
included in the age calculations (Fig. S1). The linkage disequilibrium in six ARO probands extends over a mean 
homozygous region of 5.3 cM, which equals 38 meioses/generations. With an assumed generation time of 25 
years, this corresponds to a shared ancestral origin of the SNX10 gene variant 950 years ago15.
Monocytes from patients form large osteoclasts in vitro. We isolated CD14+ monocytes from the 
peripheral blood of three patients, (Pt1, Pt2 and Pt5) and seven healthy controls, designated C1–C7. We assessed 
Patient number 1 1 1 4 5 7 8 8 9
Gender (male/female) Male Male Male Female Female Male Male Male Female
Age at the time of imaging (year) 29 34 33 35 14 2 11 11 8
MRI/CT-scan MRI MRI CT CT MRI MRI MRI CT MRI
Corpus callosum aplasia/hypoplasia 0 0 X X 0 0 0 X 0
Sclerotic bone 1 1 1 1 1 0 1 1 1
Thickened bone 1 1 1 1 1 0 1 1 1
Ventriculomegaly 0 0 0 0 0 0 1 1 0
Remodelled inner table 1 1 1 0 1 0 0 1 0
Tonsillar herniation 1 1 X 0 1 0 1 X 1
Optic nerve sheath dilatation 0 0 0 0 1 0 1 1 0
Proptosis 1 1 1 1 0 0 1 X 1
Brain atrophy 0 0 0 0 0 0 0 0 0
Optic nerve atrophy 0 0 0 X X 1 1 X 1
Optic canal stenosis 0 1 1 1 0 0 1 0 0
Ear fluid 1 1 X X 0 1 0 X 0
Dural venous sinus stenosis X X X 0 1 X 1 X 1
Foramen magnum stenosis 0 0 X X 1 0 1 X 1
Posteriorly angulated dens with stenosis X X X X 1 0 1 X 1
Cervical spinal stenosis in included upper 
part 1 1 0 0 0 0 0 0 0
Subdural hematoma or intra-cerebral 
bleeding 0 0 0 0 0 0 0 0 0
Prominent collateral veins between sinus 
transversus and extra-cranial veins 0 0 0 0 0 0 1 0 0
Lemon shape of the scull (similar to what 
is seen in Chari II malformation), syrinx 
of the cervical cord, large occipital horns
0 0 0 0 0 0 1 0 0
Calcification in basal ganglia and 
subcortical frontal lobes 0 0 0 0 0 0 0 1 0
Table 2. Magnetic resonance imaging (MRI) and computed tomography scan (CT) of the skull and brain, in 
six individuals with SNX10 related intermediate autosomal recessive osteopetrosis (IARO). 1 = present, 0 = not 
present, X = feature not possible to evaluate.
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osteoclastogenesis on both plastic and bone slices, by incubating CD14+ monocytes with RANKL. Cells from 
patients were tested alongside control cells in six different independent experiments. The data are presented sep-
arately for these individual experiments instead of being pooled because of the large inter-individual variability 
that is commonly seen in primary osteoclast cultures from humans.
Multinucleated cells that stained positive for tartrate resistant acid phosphatase (TRAP+) were formed on 
plastic dishes in all cultures from patients and controls. The TRAP+ multinucleated cells (TRAP+MuOCL) from 
patients were larger and stained less intensely for TRAP than those from controls (Fig. 2A,B). Accurate counting 
of TRAP+MuOCL in patient cultures was difficult as osteoclasts in patient cultures were large and pale.
The patient TRAP+MuOCL formed peripheral belts of F-actin-rich podosomes similar to controls. The cir-
cumference of these actin belts was greater in the patient osteoclasts than the control osteoclasts, reflecting the 
greater size of the patient cells (Fig. 2C).
Expression of osteoclastic and osteoclastogenic genes in cells from patients. We next assessed 
if the expression of genes associated with osteoclast differentiation and function was altered in the patient oste-
oclasts. Gene expression analyses were performed twice with cells from two patients (Pt2 and Pt5) at one time 
point during the culture, and with two different controls (C1–C4) in each analysis (Figs 3 and S2). The reason 
data are provided separately for different controls and different patients is that the logistics of the cell collections 
and experiments did not allow us to compare the same control with the same patient in each experiment. We 
Figure 2. Osteoclast differentiation of CD14 + monocytes from peripheral blood. Photographs of TRAP staining 
(A) and quantification of surface area (B) of CD14 + cells cultured in M-CSF (M) or M-CSF and RANKL (M/RL) 
for four days (C1, C2, Pt2, Pt5) or five days (C1, lower photos, and Pt1). Surfaces are presented as mean ± SEM. (C) 
Actin ring staining of cells cultured in M/RL for four days. Scale bars: 100 μm. *** P ≤ 0.001.
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performed separate experiments comparing cells from different controls and from different patients. We repeated 
the experiments at different times to ensure reproducibility of our observations.
The mRNA expression of ACP5 (encoding the enzyme TRAP) and CTSK (encoding cathepsin K), both robust 
markers of the osteoclastic phenotype, was strongly upregulated by RANKL in cells from both patients and con-
trols (Fig. 3A,B). There was no difference between patients and controls in the degree of upregulation of NFATc1 
(encoding nuclear factor of activated T-cells, the master osteoclastogenic transcription factor), (Fig. 3C). No 
differences between patients and controls were found in RANKL-induced upregulation of TCIRG1 (encoding 
the proton pump subunit, Atp6i, essential in acidification process) (Fig. 3D), or the mRNA expression of ITGAV 
and ITGB3, (encoding the αv and β3 subunits of the vitronectin receptor, essential for osteoclast attachment to 
bone) (Fig. 3E,F). The expression of CLCN7 (encoding chloride channel 7, with an essential role in acidification) 
was consistent throughout osteoclastogenesis in cells from both patients and controls (Fig. 3G). Although some 
genes showed a significant difference between patient and controls in one of the two independent experiments, 
none of the analyzed genes were significantly and reproducibly changed in both patients compared to controls. 
These data indicate that the SNX10 mutation does not affect the expression of key genes associated with osteoclast 
differentiation and function.
The ability of osteoclasts with the SNX10 mutation to resorb bone was analysed by culturing CD14+ cells from 
patients on slices of devitalized bovine bone in six different experiments, each comparing cells from one of 3 
patients with several of 7 controls. In control cultures, RANKL stimulated the formation of many TRAP+MuOCL. 
In patient cultures we observed TRAP+MuOCL, but, as in cultures on plastic, we also noticed several much larger 
cells with weak TRAP staining, making accurate counting of the number of osteoclasts impossible (Fig. 4A). We, 
therefore, also used TRAP5b released into the culture media as a parameter of mature osteoclast formation16, but 
found no consistent difference between patients and controls (data not shown).
Phalloidin staining demonstrated that control osteoclasts frequently exhibited crescent-shaped actin rings, 
which were associated with extensive resorption pits and resorption trails in the bone slices (Fig. 4B,C) and 
release of CTX (a degradation fragment from collagen type I) (Fig. 4D). Patient osteoclasts polarized their actin 
Figure 3. Gene expression in osteoclasts from patients (Pt2, Pt5), and controls (C1, C2, C3, C4). Fold induction 
of gene expression between cells treated with M-CSF (M) with and without RANKL (RL) for three days. All 
values are given as mean ± SEM (n = 4). *P ≤ 0.05, **P ≤ 0.005, ***P ≤ 0.001 between indicated groups.
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Figure 4. Patient-derived osteoclasts form actin rings but are unable to resorb bone. (A) TRAP staining 
of CD14 + cells cultured in M/RL on bone for eight days. Scale bar 40× panel: 500 μm, scale bar 100× light 
microscope and reflective light panel: 200 μm, scale bar 100× toluidine blue panel: 100 μm. (B,C) Osteoclasts 
were analyzed by confocal microscopy; (B) stained with TRITC-phalloidin (red), DAPI (blue) and the bone 
surface using a fluorescent bisphosphonate (AF-ALN; green). Resorption pits stain brightly with AF-ALN and 
can be seen in the control only. Scale bar = 100 μm; (C) stained with TRITC-phalloidin (red), DAPI (blue) AF-
ALN (magenta) and the cell membranes with wheat germ agglutinin (green). AF-ALN omitted from upper 
panel of Pt2 for clarity. Black patches in C2 xy image indicates resorption pits. Bottom panel of Pt2 is a zoom of 
the zx section illustrating lack of resorption. Scale bar = 20 μm; (D) CTX-1 release in media during day 6 to 8 of 
culture in M/RL. C1, C6 = controls, Pt2, Pt5 = patients (n = 4–5).
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cytoskeleton in rings at the periphery of the cells, similar to the actin belts seen in cells on plastic. Patient cultures, 
however, showed no evidence of resorption. There were no resorption pits (Fig. 4A–C) and there was no release of 
CTX (Fig. 4D). There was no evidence of vacuolation in any of the patient osteoclasts (Fig. 4B).
Increased size of patient osteoclasts is independent of precursor fusion. Individual patient oste-
oclasts occupied larger areas of the bone surface than control osteoclasts (Fig. 4A–C), similar to the observations 
on plastic (Fig. 2A–C). However, osteoclasts on bone from patients contained similar numbers of nuclei as those 
from healthy controls (mean nuclei/osteoclast = 7.3 for C1, 7.8 for C2, 7.9 for Pt2). Patient osteoclasts were much 
flatter than the control osteoclasts; in cross-sectional views most osteoclasts were no deeper than a single nucleus 
(Fig. 4C). This indicates that the larger size of the patient osteoclasts is the result of increased spreading, rather 
than the result of increased fusion.
In agreement with these findings, we were unable to observe any significant differences replicated in two 
separate experiments between expressions of several genes suggested to be involved in osteoclast fusion (Fig. S2). 
RANKL-induced upregulation of the osteoclast fusion genes DC-STAMP and OC-STAMP17–19 was similar in cells 
from patients and controls (Fig. S2). Syncytin-1 and its receptor Asct2 have also been suggested to be involved in 
osteoclast fusion20 but the mRNA expression of the genes encoding these proteins (ERVW-1 and SLC1A5, respec-
tively) was not different between patients and controls (Fig. S2).
Osteoclasts exhibiting SNX10 mutation have an impaired ruffled border. Since osteoclast forma-
tion and F-actin ring formation was unaffected, we speculated that the lack of resorption by osteoclasts derived 
from the patients would be due to defective ruffled border formation, similar to well-characterized cases of 
osteoclast-rich ARO21. This would be consistent with the likely role of SNX10 in vesicular trafficking processes 
in osteoclasts. While control osteoclasts on bone accumulated PNA-lectin (a marker of the ruffled border)22, 23 
within the actin ring, patient osteoclasts showed no PNA-lectin staining (Fig. 5A), suggesting impaired ruffled 
border formation in the patient osteoclasts.
Transmission electron microscopy was used to further examine the sealing zone (F-actin rings) and the ruf-
fled border in cultured osteoclasts. This ultrastructural analysis confirmed that patient osteoclasts retained the 
capacity to form sealing zones (Fig. 5E), but that 65% of patient osteoclasts lacked ruffled borders (Grade 0) 
and showed no evidence of bone resorption. In contrast, control osteoclasts showed evidence of extensive bone 
resorption and only 18% of these cells lacked ruffled border (Fig. 5B,D and F). Fifteen percent of patient osteo-
clasts showed moderate/extensive ruffled borders, compared to 50% of control osteoclasts. The ultrastructural 
analysis confirmed that patient osteoclasts were very large and flat compared to control cells, with sealing zones 
located at the cell periphery.
Gene expression of wild type and mutated SNX10. SNX10 mRNA levels were measured in 
RANKL-stimulated CD14+ cells using two different TaqMan assays, spanning the junction between exon 1–2 
and 4–5, respectively. SNX10 mRNA, analyzed with the exon 1–2 assay, was present in patients and controls and 
significantly upregulated by RANKL in controls and in one of the two patients (Fig. 6A). However, the mRNA 
levels were lower in patient cells. The assay spanning the exon 4–5 junction also showed upregulation of SNX10 
by RANKL in control cells (Fig. 6B). However, as the mutation is located at the splice donor site of exon 4, this 
domain was barely detected in cells from patients.
Discussion
We herein report the clinical features and natural course of the Västerbotten form of IARO [MIM 615085], the 
disease-causing mutation, its origin and age. We also present functional analyses of the effects of this mutation on 
osteoclast differentiation and function.
The Västerbotten form of IARO is caused by a splice site mutation in the SNX10 gene [MIM 614780] 
c.212 + 1 G > T12 resulting in a frame shift and a stop codon (p.S66Nfs * 15). The carrier frequency was found 
to be 1/93 in the population of Västerbotten. According to haplotype analysis, the shared ancestral origin of the 
SNX10 gene variant is approximately 950 years old.
The phenotype of IARO, previously associated with mutations in the PLEKHM1, CLCN7, and CA2 genes1–3, 21, 24, 
is defined as asymptomatic at birth, with patients exhibiting fractures by the end of their first decade of life, 
while bone marrow failure and hepato-splenomegaly are rare24–27. In contrast, our data show that patients with 
SNX10-related IARO of Västerbotten type described here have a more severe phenotype, with age at onset in 
early infancy, presenting with optic atrophy, macrocephaly, frontal bossing, proptosis, and anemia. Splenomegaly, 
due to compensatory extra-medullary hematopoiesis, was present before the age of five, and splenectomy was 
performed in three patients (Pt1, Pt8, and Pt9), the youngest at the age of five years (Pt1). Although the patients 
displayed many of the symptoms seen in malignant ARO, they all survived early childhood without being trans-
planted. We, therefore, placed the patients in the group of IARO, rather than in the group of malignant ARO in 
which patients do not survive childhood if not transplanted.
Osteopetrosis presenting with hydrocephalus, hind-brain posterior fossa crowding, foramen magnum nar-
rowing, and syringohydromyelia is rare, but has been described in the literature28–31. Cure et al. studied cranial 
MRI of osteopetrosis, but did not identify ventriculomegaly, tonsillar herniation, or remodelled inner table in 
IARO32. In the Västerbotten intermediate form of osteopetrosis these features seem to be common; in our study, 
four patients (Pt1, Pt5, Pt8, and Pt9) had cerebellar tonsillar descent through the foramen magnum, and three 
(Pt1, Pt5, and Pt8) of them showed remodelled inner table. Three subjects (Pt5, Pt8, and Pt9) had foramen mag-
num stenosis, posteriorly angulated dens with stenosis and signs of brain stem compression.
Structural brain malformation is rarely reported as part of the clinical spectrum of osteopetrosis, but cerebral 
atrophy, corpus callosum agenesis, hypoplasia of the hippocampus, and Dandy-Walker malformation has been 
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reported33–36. However, none of our SNX10 related IARO patients had intra-cerebral malformations. MRI of 
the brain showed calcification of the basal ganglia, and subcortical frontal lobes in one male patient (Pt8), who 
died due to spinal cord compression caused by a combination of prominent calvarial and skull base thickening, 
Figure 5. Patient-derived osteoclasts formed defective ruffled borders. (A) Phalloidin staining for acting rings 
(left) and lectin staining for ruffled border (middle) of CD14 + cells cultured in M/RL on bone for 11 days. 
(B–E)-Representative TEM micrographs of control C2 (B,C) and patient Pt2 (D,E) -derived osteoclasts show 
extensive ruffled border (grade 3) and resorption in the control, compared to lack of ruffled border (grade 0) 
and resorption in the patient. Patient osteoclasts formed sealing zones (E). N = nucleus, SZ = sealing zone, 
RB = ruffled border. Scale bars in left panels = 2 μm. Scale bars in right panels = 500 nm. (F) The percentage of 
osteoclasts categorized into each ruffled border grade (control, n = 38; patient, n = 34).
www.nature.com/scientificreports/
1 1Scientific RepoRts | 7: 3012  | DOI:10.1038/s41598-017-02533-2
toncillar herniation, foramen magnum narrowing and posteriorly angulated dens with stenosis. He also had ven-
triculomegaly, dural venous sinus stenosis, and remodelled inner table as a sign of elevated intra-cranial pressure. 
MRI also showed collateral veins between sinus transversus and extra-cranial veins, possibly caused by a jugular 
foramen stenosis, occlusion of the jugular vein and thrombosis of the transverse and sagittal sinuses, which is 
not previously described in subjects with IARO. However, no brain phenotype was reported in Snx10 knock out 
mice37. Calcification of basal ganglia, dura mater, tentorium cerebelli and periventricular calcification extending 
into the white matter (Marble brain disorder) has previously been described with or without association to renal 
tubular acidosis due to carbonic anhydrase II deficiency38–41. The reason for calcification of the brain is unclear.
Results of studies performed in Snx10 knock out mice suggest an additional role for Snx10 in the gastric 
epithelium. Snx10 knock out mice have impaired gastric acidification and are severely hypocalcaemic com-
pared to wild type littermates, resulting in rickets as well as osteopetrosis (osteopetrorickets). In contrast, 
osteoclast-specific knockout of Snx10 resulted in osteopetrosis without rickets or alterations in calcium balance37. 
Interestingly, the patients in the present study have no signs of rickets. Also, SNX10 osteopetrotic patients have 
been shown to be almost completely rescued from the sclerotic phenotype by hematopoietic stem cell transplan-
tation12. Considering the results of these studies, there seems to be a difference in the importance of SNX10 in 
different organs in mice and humans.
Using RANKL-stimulated peripheral blood monocytes we found that osteoclasts could be generated from 
cells isolated from the patients bearing the SNX10 splice site mutation. This is consistent with previous stud-
ies, which were also able to generate osteoclasts from peripheral blood of patients with different SNX10 muta-
tions10, and from spleen or bone marrow cells of Snx10 KO mice37, 43. In contrast, silencing of Snx10 in the mouse 
pre-osteoclastic cell line Raw 264.7 was shown to inhibit RANKL-induced osteoclast differentiation42. Moreover, 
SNX10 mRNA levels were increased during RANKL-stimulated osteoclastogenesis, consistent with a likely role 
in osteoclast function rather than formation. Although we have not been able to obtain bone biopsies from the 
patients, these findings suggest that the patients have an osteoclast-rich form of osteopetrosis.
The osteoclasts generated from patients had normal expression of key osteoclast genes including those asso-
ciated with osteoclast fusion and bone attachment, however, the osteoclasts were larger than in healthy controls. 
There was not difference in the number of nuclei per osteoclasts between patients and controls, indicating that the 
larger size is the result of increased spreading, similar to what is seen in other cases of IARO21. By contrast, Aker et 
Figure 6. Expression of SNX10 mRNA in cells treated with M or M/RL for three days, analyzed with an assay 
covering the exon 1–2 (A) and exon 4–5 (B) junction. Values are given as mean ± SD (n = 2–4). ***P ≤ 0.001 
between M and M/RL treated cells.
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al. reported that osteoclasts generated from patients with a missense mutation (Arg51Gln) in SNX10 were fewer 
in number and smaller than in controls and, similar to osteoclasts from the Snx10 null mouse, had a markedly 
decreased capacity to dissolve calcium phosphate10, 37, 43. Our data show that osteoclasts cultured from patients 
were unable to resorb bone, evidenced by both an absence of resorption pits and lack of CTX in the culture super-
natant. This finding is identical to earlier findings with osteoclasts cultured from IARO patients bearing muta-
tions in PLEKHM121. Interestingly, human osteoclasts with a missense SNX10 mutation10, and mouse osteoclasts 
from Snx10 null mice37, 43 although having reduced activity, still had some capacity to dissolve calcium phosphate 
film, whereas human osteoclasts from our patients did not show any evidence of bone resorbing activity. This 
discrepancy most likely is due to the use of crystalline calcium phosphate coating instead of bone as substrate for 
the assessments of the bone resorbing activity.
Electron microscopy revealed that the inability of osteoclasts from osteopetrotic patients in the Västerbotten 
County to resorb bone is associated with defective ruffled border formation, very similar to patients with ARO 
caused by mutations in other genes4, 21, 44. Using phalloidin staining, we found that the SNX10 patient osteoclasts 
were still able to form F-actin rich podosome belts in plastic dishes and normal F-actin rings when cultured on 
bone. In agreement with these observations, electron microscopy demonstrated these osteoclasts formed a seal-
ing zones with normal appearance. These observations indicate that the defect lies in the endosomal/lysosomal 
trafficking pathways associated with ruffled border formation. This is perhaps not surprising, since SNX10 is a 
member of the sorting nexin family of proteins that play crucial roles in cargo sorting in the endosomal path-
way45, 46, moreover; other genetic mutations that cause osteoclast-rich ARO also affect this pathway4. In contrast 
to these findings, osteoclasts generated from bone marrow macrophages with deletion of the Snx10 gene have 
been reported to form an abnormal F-actin positive podosome belt in plastic dishes43. We have no explanation for 
these differences between mouse and human osteoclasts. As discussed below, we do not believe that the difference 
might be due to expression of a truncated, functional form of SNX10 in our patients.
There seem to be clear differences in the functional consequences for osteoclasts in patients with the Arg51Gln 
mutated SNX1010 and those in the present study. Thus, the Arg51Gln mutation results in decreased osteoclast for-
mation and decreased osteoclast activity, whereas the SNX10 mutation found in the Västerbotten form of IARO 
impairs resorption by disrupting ruffled border formation in mature osteoclasts. Furthermore, osteoclasts with 
the Arg51Gln mutation exhibit extensive cytoplasmic vacuolation, which was not seen in osteoclasts with the 
Västerbotten mutation. Increased vacuolation has also been observed by overexpressing SNX10 in several human 
cell lines47, which raises the possibility that the Arg51Gln mutation results in gain of function; however, overex-
pression of the Arg51Gln form of SNX10 does not cause vacuolation48, therefore, the functional consequences of 
this mutation remain unclear. No full length SNX10 protein can be expressed in osteoclasts with the Västerbotten 
mutation, as the mutation leads to a stop codon upstream from intron 4. We do not know whether a truncated 
form of SNX10 is expressed but we have not been able to conclusively show the presence of a truncated SNX10 
protein using four different antibodies in Western blots, including antibodies recognizing the amino-terminal 
part of SNX10. SNX proteins contain a conserved phox-homology (PX) domain, which can bind phosphorylated 
phosphatidylinositols (PI), thereby targeting SNXs to PI-enriched membranes. The PX domain extends from 
c.30–381 in exons 3–6. It seems as if the PX domain in SNX10 is even further extended (PXe) in the C-terminal 
part48, 49. Since PX or PXe is the functional domain in SNXs, it is unlikely, even if a truncated SNX10 protein is 
expressed in osteoclasts carrying the Västerbotten mutation, that this truncated protein has any biological activity. 
The difference between the Arg51Gln mutation and the Västerbotten mutation is most likely responsible for the 
differences seen in osteoclast formation and function.
In conclusion, the Västerbotten intermediate form of osteopetrosis is caused by a splice site sequence variant 
in the SNX10 gene and differs in clinical characteristics from other intermediate types of ARO. The age at onset 
is early in infancy, optic atrophy and anemia is present at diagnosis and tonsillar herniation, foramen magnum 
stenosis, and severe osteomyelitis/osteonecrosis of the jaw are common. Osteoclasts generated from peripheral 
blood monocytes of the patients showed defects in ruffled border formation and failed to resorb bone. These 
data extend the clinical spectrum of IARO and demonstrate a critical role for SNX10 in ruffled border formation.
Materials and Methods
Subjects. We collected clinical data, medical records, x-ray, computed tomography scan (CT) and magnetic 
resonance imaging (MRI) of the brain, and blood samples from five male and four female patients with IARO. We 
also collected blood samples from their parents and siblings. Patients descended from the county of Västerbotten, 
northern Sweden.
Exome sequencing. DNA from three patients and 15 non-related individuals (controls) from the county 
of Västerbotten were sequenced. Exome enrichment was performed using 3 μg genomic DNA. DNA samples 
were sheared by sonication with the Covaris S2 instrument (Covaris, Inc.). Fragment libraries were constructed 
from the sheared samples using the AB Library Builder System (Life Technologies) and target enrichment was 
performed according to the manufacturer’s protocols (Agilent SureSelect Human All Exon v3 kit). Exome capture 
was conducted by hybridizing the DNA libraries with biotinylated RNA baits for 24 h followed by extraction using 
streptavidin coated magnetic beads. Captured DNA was then amplified followed by emulsion PCR using the EZ 
Bead System (Life Technologies) and sequenced on the SOLiD5500xl system. Individual libraries were labelled 
by a post-hybridization barcoding procedure (Agilent, Santa Clara, CA, USA; barcodes compatible with SOLiD 
sequencing technology).
Alignment and variant calling. Alignment of color space reads to the human reference genome (GRCh37/
hg19) was performed using v2.1 of the Lifescope Software (Life Technologies). Single nucleotide variants (SNVs), 
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and small insertions and deletions (indels) were subsequently identified by the diBayes algorithm available within 
the Lifescope software. All identified SNVs and indels were imported into a local installation of the CanvasDB 
database system13, for annotation and further analysis of the variants.
DNA and cDNA sequencing, haplotype analysis, carrier frequency. DNA was extracted from whole 
blood using a standard salting-out method. SNX10 gene amplification and bidirectional sequencing of exons and 
intron-exon boundaries were performed in samples from all patients and their parents. RNA was extracted from 
cultured patient peripheral blood monocytes and converted to cDNA as described below for gene expression 
analysis. Bidirectional Sanger sequencing (Applied Biosystems BigDye Terminator v3.1 Cycle Sequencing Kit, 
Applied Biosystems) on a 3730xl DNA Analyzer (Applied Biosystems) was used for analysis of SNX10 cDNA 
(NM_001199837.1) using primer in exon 3 to 5 to confirm the mutation and to identify the effect of the splicing. 
Sequence analysis was performed using the Sequencher software (Gene Codes Corporation, Ann Arbor, MI, 
USA). Primers sequences where designed using Primer 3 Plus software (primer3plus.com/) and are available 
upon request. Five patients (Pt1–5) were analyzed using the GeneChip Mapping 250 K array (Affymetrix, Santa 
Clara, CA), and one patient (Pt9) was analyzed using the HumanOmniExpressExome-8v1array (Illumina), for 
haplotype analysis, and estimation of the age of the sequence variant. To calculate the carrier frequency, DNA 
from 1000 randomly chosen individuals from the county of Västerbotten was used (The medical bio-bank, Umeå 
university hospital, Umeå, Sweden)50.
In vitro culture of CD14+ monocytes from patients and controls. Peripheral blood mononuclear 
cells were isolated by Ficoll-Paque PLUS separation and CD14+ cells were labelled with CD14 MicroBeads and 
extracted using a MACS column according to the manufacturer’s instructions (Miltenyi). Cells were then seeded 
in 96-well plates (3 × 105 cells/cm2) in complete α-MEM medium (Gibco cat no 22561-021) supplemented with 
10% heat inactivated fetal bovine serum (FBS, Sigma cat no F7524), 2 mM GlutaMAX (Gibco cat no 35050-038), 
50 µg/ml gentamicin (Gibco cat no 15750-037), 100 U/ml penicillin and 100 µg/ml streptomycin (Gibco cat no 
15140-148) and 30 ng/ml human M-CSF (M, R&D Systems cat no 216-MC-025/CF). For osteoclast generation, 
2 ng/ml recombinant mouse RANKL (RL, R&D Systems cat no 462-TEC-010) was added from the start of the 
experiments (day 0). Media was replenished every three days and the cells were stained for TRAP at different days 
of culture using the Acid Phosphatase, Leukocyte (TRAP) Kit from Sigma (cat no 387A). TRAP+ cells containing 
three or more nuclei were counted as TRAP+ multinucleated osteoclast (MuOCL).
Analysis of osteoclast differentiation, gene expression and bone resorption. RANKL-stimulated 
osteoclast differentiation of CD14+ cells was analyzed on plastic and on devitalized bovine bone discs (IDS 
Immunodiagnostics Systems cat no TDT-1BON1000-96). The surface area of TRAP positive cells on plastic 
were analyzed using the OsteomeasureTM software (v3.2.1.0, Osteometrics Inc.). Total RNA was purified from 
cells at day 3 using RNeasy Micro Kit (Qiagen). cDNA synthesis was performed using the High Capacity cDNA 
Reverse Transcription Kit from Applied Biosystems. Gene expression was analyzed in two different experiments 
with in total four healthy controls and two patients using predesigned TaqMan Assays (Life Technologies) and 
the StepOnePlus Real-Time PCR system (Applied Biosystems). We analyzed ACP5 (Hs00356261_m1), CTSK 
(Hs01080388_m1), NFATc1 (Hs00542678_m1), TCIRG1 (ATP6i, HS00990751_m1), CLC7 (Hs01126462_
m1), ITGAV (Hs00233808_m1), ITGB3 (Hs01001469_m1), DC-STAMP (Hs00229255_m1), OC-STAMP 
(Hs00875776_m1), ERVW-1 (Syncytin-1, Hs02341206_g1), SLC1A5 (Asct2, Hs00194540_m1), SNX10 exon 2–3 
(Hs01007224_m1) and SNX10 exon 4–5 (HS01007226_m1). The mRNA abundance of each gene was adjusted 
for the expression of 18S (Life Technologies 4310893E) used as an internal control. In most figures, gene expres-
sion is presented as the fold increase between M/RL and M treated cells. Statistical analysis was performed using 
One-Way ANOVA with Tukey’s post hoc test. The bone resorptive activity of osteoclasts on bone slices was ana-
lyzed by measuring the release of C-terminal telopeptides of type I collagen (CTX) in culture supernatants using a 
commercial ELISA (IDS Immunodiagnostics Systems cat no AC-07F1) and by Toluidine blue staining of positive 
excavations. TRAP5b was analyzed in culture media using commercial ELISA (IDS Immunodiagnostics Systems 
cat no SB-TR201A).
Staining for the actin ring and ruffled border. Actin organization was studied at day 4 on plastic and 
day 11 on bone. Cells were fixed in 4% paraformaldehyde, washed with PBS and then permeabilised using 0.1% 
Triton X-100 in PBS for 10 min at 4 °C. After washing again with PBS, the cells were stained with rhodamine 
conjugated phalloidin (Life Technologies cat no R415), 5 U/ml in 2% BSA/PBS, for 20 min at 4 °C. Following 
washing in PBS the cells were mounted in Prolong Gold Mountant (Life Technologies cat no P-36931). Cells 
cultured on bone were stained for phalloidin as above but including 100 µg/ml FITC conjugated peanut aggluti-
nin (PNA)-lectin (Sigma cat no L7381) to stain the ruffled border22, 23. Photographs were taken using widefield 
fluorescence microscopy.
Confocal microscopy. Osteoclasts cultured on bovine bone discs were prepared as above, and, in addition to 
phalloidin, were stained with 5 μg/ml Alexa Fluor 633-conjugated wheat germ agglutinin to stain cell membranes 
and 10 μM Alexa Fluor 488-conjugated alendronate (AF-ALN, ref. 51) to stain bone surfaces. Bone discs were 
mounted on to glass slides in VectaShield with DAPI (to stain nuclei) mounting medium before analyzing on a 
Zeiss LSM700 confocal microscope. To assess potential differences in fusion, the number of nuclei was counted 
in 80 randomly selected osteoclasts from two control cultures and one patient culture.
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Transmission Electron Microscopy investigation of ruffled border morphology. To investigate 
whether patient osteoclasts were capable of forming mature ruffled borders, cells cultured on bovine bone were 
analyzed by transmission electron microscopy (TEM). Briefly, cell cultured with M-CSF and RANKL for eight 
days were fixed in 2.5% glutaraldehyde in 0.1 M cacodylate buffer. The bone discs were then demineralized in 
0.15 M EDTA before being postfixed in 1% osmium tetroxide and embedded in Epon resin. Bone discs were 
sectioned perpendicular to the bone surface to obtain cross sections of osteoclasts and their ruffled border areas. 
Ultrathin sections were imaged using a JEOL Jem-1400Plus TEM equipped with an AMT UltraVUE camera. 
Following image acquisition, osteoclasts were graded based on their ruffled border morphological characteristics, 
similarly to a previous study, ref. 52: grade 0 - no ruffled border apparent; grade 1 - rudimentary ruffled border, 
with few poorly-developed membrane folds apparent; grade 2 - moderate ruffled border, with folded membrane 
apparent at some areas; grade 3 - extensive, highly-folded ruffled border.
Statistics. For experiments with two patients and two controls, statistical analysis was performed using 
One-Way ANOVA with Tukey’s post hoc test. When one patient was compared to one control, a two-sided 
Student’s t test was used. A difference was considered statistically significant with P < 0.05. Due to the limited 
number of patients and the large inter-patient variation, it was not possible to pool the results and make statistical 
comparisons based on the patients as one group. Instead, the results are shown for each patient separately. For 
gene expression analyses (Figs 3 and S1) each independent experiment is shown.
Study approval. The Regional Ethical Review Board at Umeå University, Umeå, Sweden, approved the study. 
Patients, parents or first-degree relatives gave their written informed consent. Methods using human tissue were 
in accordance with the Helsinki declaration.
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